Summer 2024

Machine Learning Intern

Posted on 4/12/2024

Recursion

Recursion

501-1,000 employees

Data-driven drug discovery platform leveraging datasets

No salary listed

Toronto, ON, Canada

Category
AI & Machine Learning (3)
, ,
Required Skills
Kubernetes
CUDA
Data Structures & Algorithms
Pytorch
BigQuery
Docker
Pandas
NumPy
Linux/Unix
Google Cloud Platform
Requirements
  • Expert knowledge of deep learning theory and practice
  • Experience working with biological data (microscopy, genetics, rnaSeq, etc.)
  • Contribute to the development or implementation of deep learning algorithms and architectures, particularly leveraging self-supervised learning
  • Run large scale experiments evaluating 100s of hyper parameters
  • Run and interpret benchmarks for assessing model performance
  • Contribute to conference and journal publications
  • Experience with PyTorch, NumPy, Pandas, GCP, Hybrid Cloud, Linux, CUDA, Docker, Kubernetes, BigQuery, large scale distributed systems
Responsibilities
  • Contribute to developing algorithms and architectures and training models on large biological datasets
  • Leverage Recursion’s leading supercomputer, training models across 100s of GPUs
  • Explore properties of the resulting representation model on a range of benchmarks
  • Work collaboratively alongside machine learning engineers, scientists, and product managers

Recursion uses hardware, software, and data to accelerate drug discovery in the TechBio space, running thousands of wet-lab experiments weekly to profile genes and compounds across many cell types. It combines a massive proprietary dataset (about 50 petabytes) with a powerful computing platform, BioHive 1, to map billions of gene–compound relationships and generate actionable drug candidates. Its approach blends high-throughput experimentation with large-scale data science to create learning loops and partnerships with pharmaceutical companies, research institutions, and healthcare providers. Its goal is to decode biology at scale and discover and commercialize medicines that can improve patient lives.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Salt Lake City, Utah

Founded

2013

Your Connections

People at Recursion who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • REC-4881 showed 43% median polyp reduction at 12 weeks and 53% at Week 25, proving durable efficacy in FAP.
  • REC-4881 received Fast Track and Orphan Drug designations, accelerating regulatory pathways toward Phase 3 development.
  • Recursion's AI platform identified REC-4881 as a top rescue hit, demonstrating platform-driven discovery and strong clinical validation.

What critics are saying

  • Roche dependency caused 56% revenue drop in Q1 2026, with high risk of further collapse if no new milestones secured.
  • Cash burn of $390M annually leaves runway only into early 2028; dilution or bankruptcy likely if trials fail or funding stalls.
  • Clinical trial failure of REC-4881 or REC-1245 could erase investor confidence and trigger stock collapse to under $1.97 valuation.

What makes Recursion unique

  • Recursion is the only end-to-end AI-native biotech company decoding biology via its proprietary Recursion OS.
  • The company industrializes drug discovery using 50 petabytes of data, 2.2M weekly wet lab experiments, and BioHive 1 supercomputer.
  • Recursion identified MEK1/2 as APC rescue through unbiased phenotypic screening, validating its platform's ability to discover novel biology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Hybrid Work Options

INACTIVE